Proliferative activity and p53 expression in primary and recurrent pterygia
Section snippets
Subjects and methods
Formalin-fixed, paraffin-embedded sections of pterygium and conjunctival tissues from the ophthalmic pathology laboratory at the Hadassah University Hospital, Jerusalem, Israel, were used for the study. Subjects who underwent pterygium removal without mitomycin-C application, and who were prospectively followed for more than 12 months, were included in the study. Four groups of pterygia were studied. Pterygium tissue from 10 consecutive patients who did not have recurrence of the
Results
MIB-1 yielded a red nuclear stain in epithelial cells from all the tissue in all groups (Fig 1A). There was no significant difference among the proliferative activities of the four groups as estimated by the mean MIB-1 positive cell count per eyepiece grid (P = 0.17, Kruskal-Wallis test). However, there was a trend toward higher proliferative activity in epithelium overlying the pterygium compared with normal conjunctival epithelium (mean MIB-1 positive cell count/grid ± standard error was
Discussion
We found p53 immunoreactivity in half of the primary (groups A and B) and recurrent (group C) pterygia. Interestingly, we did not find a difference in p53 immunoreactivity between eyes with primary pterygium that did not recur and primary pterygium that was followed by recurrence of the pterygium. Most of the recurrences of primary p53-positive pterygia were p53 negative. In addition, proliferative activity of primary pterygia that recurred (group B) was similar to that of primary pterygia
References (13)
- et al.
Use of mitomycin C with conjunctival autograft in pterygium surgery in Asian-Canadians
Ophthalmology
(1999) - et al.
Intraoperative application of topical mitomycin C for pterygium surgery
Ophthalmology
(1996) - et al.
Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium
Am J Ophthalmol
(1997) p53, the cellular gatekeeper for growth and division [review]
Cell
(1997)- et al.
Solar keratosis, pterygium, and squamous cell carcinoma of the conjunctiva in Malawi
Br J Ophthalmol
(1979) - et al.
Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium
Br J Ophthalmol
(1998)
Cited by (74)
The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review
2022, Experimental Eye ResearchCitation Excerpt :These p53 mutations are thought to be also involved in the pathogenesis of pterygium, which is similarly associated with the environmental risk factor of UV exposure. For example, immunohistochemical studies have identified mutant p53 (Dushku and Reid, 1997; Tsai et al., 2005b; Ueda et al., 2001) or aberrant expression of p53 (Chowers et al., 2001; Tan et al., 2000; Tsai et al., 2005a; Weinstein et al., 2002) in pterygium specimens. Reisman et al. (2004) reported monoallelic deletion of the p53 gene in a significant proportion (44.4%) of pterygium cases; however, the remaining WT p53 allele was silenced by an unknown mechanism.
MicroRNA regulation of MDM2-p53 loop in pterygium
2018, Experimental Eye ResearchCitation Excerpt :To date, over 20 studies have reported p53 expression in pterygium by immunochemistry analysis, but the quantitative results were inconsistent. The proportion of pterygial samples with positive p53 expression was detected as 7.9% (Onur et al., 1998), 22.8% (Tsai et al., 2005), 37.5% (Tan et al., 1997), 50% (Chowers et al., 2001), 53.8% (Weinstein et al., 2002), 60% (Tan et al., 2000) and 100% (Dushku et al., 1999), respectively. One possible reason causing such varied results could be the sources and sensitivity of different anti-p53 antibodies.
Inactivation of p53 in pterygium influence miR-200a expression resulting in ZEB1/ZEB2 up-regulation and EMT processing
2016, Experimental Eye ResearchCitation Excerpt :Nearly all reported studies of the p53 gene in pterygia have been conducted using immunohistochemistry (IHC) staining (Weinstein et al., 2002; Tan et al., 2000; Ueda et al., 2001). Previous studies have shown that the p53 gene mutation ranges widely in pterygia, from 7.9% to 100% (Weinstein et al., 2002; Tan et al., 2000; Ueda et al., 2001; Chowers et al., 2001). Our previous research also showed that mutations in p53 genes were detected in 15.7% of pterygial samples (8 of 51) (Tsai et al., 2005).
Fibroblast biology in pterygia
2016, Experimental Eye ResearchCitation Excerpt :Thus, the stromal fibroblast which is responsible for tissue remodeling during the wound healing may be a main culprit of fibrosis in recurrent pterygia. Interestingly, positive p53 expression and high proliferative activity in the epithelium of pterygia were found not associated with recurrence (Chowers et al., 2001). On the contrary, b-FGF was strongly expressed in cultured fibroblasts of recurrent pterygia compared to those of primary pterygia suggesting that fibroblasts might have a major role in the recurrence (Kria et al., 1998).
Effect of orbital protrusion and vertical interpalpebral distance on pterygium formation
2014, Contact Lens and Anterior EyeCitation Excerpt :Heat, dry atmospheric conditions, wind, dust and similar factors have been found to be responsible in many research studies [2–4]. As well as environmental factors, hereditary factors, tear dysfunction, immunological mechanisms, viral infections such as human papillomavirus (HPV) and herpes simplex virus (HSV), chronic inflammation, various occupations and p53 tumor suppressor gene abnormalities have been shown to be related in pterygium etiology [2,5–7]. There are a many studies showing that ultraviolet B (UV-B) light in particular has a distinctive role in the pterygium pathogenesis [8–12].
Pterygium
2013, Ocular Surface Disease: Cornea, Conjunctiva and Tear Film